Nicox Highlights VYZULTATM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives
Press Release | |
Nicox Highlights VYZULTA TM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives | |
...................................
November 3. 2017 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), international ophthalmic company, today highlighted recent regulatory progress, with the approval in the United States of its partnered product, VYZULTA TM (latanoprostene bunod ophthalmic solution), 0.024% announced yesterday and provided an overview of the Company's corporate and financial developments and upcoming pipeline initiatives. Michele Garufi, Chairman and Chief Executive Officer of Nicox commented, "We are delighted that VYZULTA TM has been approved by the U.S. FDA, giving Nicox two approved products. The launch of VYZULTA TM in the United States by our partner Bausch + Lomb, anticipated by year end, will mark a key milestone in our strategy for Nicox to become a fully-integrated pharmaceutical company, from discovery through commercialization. The revenue stream from this first commercialized product using our NO-donating technology, along with that of ZERVIATE TM (cetirizine ophthalmic solution) 0.24% , expected to launch in late 2018, will help to support our pipeline programs, including advancing into Phase 2 clinical studies with our two mid-stage products: NCX 470, our second NO-donating product candidate, currently in development for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a novel formulation of fluticasone propionate for blepharitis. We are rapidly advancing our discovery and development programs to unlock the value in the Nicox pipeline and NO-donating technology." Product and Pipeline Highlights
| |
About Nicox | |
Nicox S.A. is an international ophthalmic company developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products with approved New Drug Applications, VYZULTA
TM
(latanoprostene bunod ophthalmic solution) 0.024%, licensed worldwide to Bausch + Lomb, and ZERVIATE
TM
(cetirizine ophthalmic solution) 0.24%, licensed in the U.S. to Eyevance. In addition, our promising drug-candidate pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a next-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its products or pipeline, please visit: www.nicox.com . | |
Analyst coverage | |
Bryan, Garnier & Co Hugo Solvet Paris, France
Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France | |
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. | |
Upcoming financial and business conferences | |
November 23-24 Actionaria Paris, France | |
Contacts | |
Nicox
Gavin Spencer, Executive Vice President Corporate Development T +33 (0)4 97 24 53 00 communications@nicox.com | |
Investor Relations
Europe Nicox Corporate Communications Department T +33 (0)4 97 24 53 00 communications@nicox.com |
Media Relations
United Kingdom Jonathan Birt T +44 7860 361 746 jonathan.birt@ymail.com |
United States
Argot Partners Melissa Forst T +1 (212) 600-1902 melissa@argotpartners.com |
France
NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 nicox@newcap.eu |
|
United States
Argot Partners Eliza Schleifstein T +1 (917) 763-8106 eliza@argotpartners.com |
Disclaimer | |
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the ' Document de référence, rapport financier annuel et rapport de gestion 2016 ' filed with the French Autorité des Marchés Financiers (AMF) on March 29, 2017, and in the updated and additional risk factors as of August 14, 2017, which are available on Nicox's website (www.nicox.com). | |
Nicox S.A.
Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 |
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NICOX via GlobeNewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NICOX via GlobeNewswire
HUG#2146984
By: Nasdaq / GlobeNewswire
- 03 Nov 2017
Return to news
Upcoming Life Sciences Events
- April 2024
- Pharma-Biotech Product & Company Valuation - An Introductory
- Basel: Swiss Biotech Day 2024
- London: BioTrinity 2024